JP2024513798A5 - - Google Patents
Info
- Publication number
- JP2024513798A5 JP2024513798A5 JP2023559680A JP2023559680A JP2024513798A5 JP 2024513798 A5 JP2024513798 A5 JP 2024513798A5 JP 2023559680 A JP2023559680 A JP 2023559680A JP 2023559680 A JP2023559680 A JP 2023559680A JP 2024513798 A5 JP2024513798 A5 JP 2024513798A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- ppm
- values
- crystal according
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163169340P | 2021-04-01 | 2021-04-01 | |
| US63/169,340 | 2021-04-01 | ||
| US202263321902P | 2022-03-21 | 2022-03-21 | |
| US63/321,902 | 2022-03-21 | ||
| PCT/IB2022/052982 WO2022208408A1 (en) | 2021-04-01 | 2022-03-30 | Crystalline form of a shp2 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513798A JP2024513798A (ja) | 2024-03-27 |
| JP2024513798A5 true JP2024513798A5 (enExample) | 2025-03-19 |
Family
ID=81327112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023559680A Pending JP2024513798A (ja) | 2021-04-01 | 2022-03-30 | Ｓｈｐ２阻害剤の結晶形態 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240190843A1 (enExample) |
| EP (1) | EP4313307A1 (enExample) |
| JP (1) | JP2024513798A (enExample) |
| KR (1) | KR20230165309A (enExample) |
| AU (1) | AU2022252094B2 (enExample) |
| BR (1) | BR112023019479A2 (enExample) |
| CA (1) | CA3215295A1 (enExample) |
| MX (1) | MX2023011664A (enExample) |
| WO (1) | WO2022208408A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12391708B2 (en) | 2019-07-18 | 2025-08-19 | Tapi Croatia Industries Ltd | Crystalline Lorlatinib : fumaric acid and solid state form thereof |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| AU2023285116A1 (en) | 2022-06-10 | 2024-12-19 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001039975A (ja) * | 1999-07-26 | 2001-02-13 | Eisai Co Ltd | スルホキシド誘導体の結晶およびその製造法 |
| CZ20031098A3 (cs) * | 2000-10-20 | 2003-08-13 | Eli Lilly And Company | Nová krystalická forma 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]fenoxy)-2-(4-methoxyfenyl)benzo[b]thiofen hydrochloridu |
| ES2416354T3 (es) * | 2005-06-21 | 2013-07-31 | Ajinomoto Co., Inc. | Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo |
| US10287266B2 (en) * | 2015-06-19 | 2019-05-14 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| PH12019500056B1 (en) * | 2016-07-12 | 2024-01-31 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| WO2018172984A1 (en) * | 2017-03-23 | 2018-09-27 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
| JP7356414B2 (ja) | 2017-09-07 | 2023-10-04 | レヴォリューション・メディスンズ，インコーポレイテッド | がんを治療するためのｓｈｐ２阻害剤組成物および方法 |
| SG11202002941WA (en) * | 2017-10-12 | 2020-04-29 | Revolution Medicines Inc | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| CA3084058A1 (en) * | 2017-12-15 | 2019-06-20 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric shp2 inhibitors |
| MX2021002880A (es) | 2018-09-14 | 2021-06-04 | Unilever Ip Holdings B V | Evaluacion de la eficacia de composiciones cosmeticas que no se deben enjuagar para proteger la piel de los contaminantes. |
| IL320682A (en) * | 2019-04-02 | 2025-07-01 | Array Biopharma Inc | Protein tyrosine phosphatase inhibitors |
-
2022
- 2022-03-30 MX MX2023011664A patent/MX2023011664A/es unknown
- 2022-03-30 KR KR1020237037693A patent/KR20230165309A/ko active Pending
- 2022-03-30 WO PCT/IB2022/052982 patent/WO2022208408A1/en not_active Ceased
- 2022-03-30 BR BR112023019479A patent/BR112023019479A2/pt unknown
- 2022-03-30 AU AU2022252094A patent/AU2022252094B2/en active Active
- 2022-03-30 EP EP22715194.1A patent/EP4313307A1/en active Pending
- 2022-03-30 JP JP2023559680A patent/JP2024513798A/ja active Pending
- 2022-03-30 CA CA3215295A patent/CA3215295A1/en active Pending
- 2022-03-30 US US18/553,214 patent/US20240190843A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2183244B1 (en) | Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt | |
| JP5242718B2 (ja) | ２，５−ジオン−３−（１−メチル−１ｈ−インドール−３−イル）−４−［１−（ピリジン−２−イルメチル）ピペリジン−４−イル］−１ｈ−インドール−３−イル］−１ｈ−ピロール一塩酸塩の結晶 | |
| EP3572409B1 (en) | 1,3,5-triazine derivative salt, crystal, preparation method, pharmaceutical composition and use thereof | |
| CN111201235B (zh) | 劳拉替尼游离碱水合物的结晶形式 | |
| JP2020536893A5 (enExample) | ||
| AU2022252094B2 (en) | Crystalline form of a shp2 inhibitor | |
| TW200932214A (en) | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-l-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide | |
| KR20090081026A (ko) | Ｍｇｌｕｒ5 수용체 길항제의 다형체 | |
| KR20180008594A (ko) | 약제학적 공-결정 및 그의 용도 | |
| CN110546147B (zh) | 苯氧基喹唑啉化合物及其在治疗癌症中的用途 | |
| CN117279903A (zh) | 作为nlrp3抑制剂的化合物 | |
| KR102531772B1 (ko) | Cdk4/6 키나아제 억제제를 타겟팅하는 결정형 | |
| EP3101020A1 (en) | Deuterated quinazolinone compound and pharmaceutical composition comprising same | |
| JP2022547208A (ja) | ニコチニルアルコールエーテル誘導体のマレイン酸塩、その結晶形、及びその使用 | |
| JP2025509818A5 (enExample) | ||
| CN109563083B (zh) | 喹唑啉衍生物类酪氨酸激酶抑制剂的盐及其晶型 | |
| KR20220130771A (ko) | 아릴아미노퓨린 유도체의 염, 그의 제조 방법 및 그의 용도 | |
| AU2015392050B2 (en) | Fumarate of pyridylamine compound and crystals thereof | |
| JP2026502614A (ja) | Ｃｄｋ阻害剤およびその薬学的に許容される塩の結晶形ならびにそれらの使用 | |
| KR102501514B1 (ko) | 2'-아미노-6-(2-아미노-6-(1-이소프로필피페리딘-4-일)-5-메틸피리미딘-4-일)-3'-플루오로-[2,4'-바이피리딘]-5-올 3염산염 및 이를 포함하는 약제학적 조성물 | |
| CN121941680A (zh) | (s)-3-((6-氟吡啶-3-基)甲基)-1-(5-(吡啶-4-基)-4h-1,2,4-三唑-3-基)哌啶-2-酮苯磺酸盐 | |
| KR20210029693A (ko) | 2,6-비스-(2-아미노피리미딘-4-일)피리딘-3-올 2염산염 및 이를 포함하는 약제학적 조성물 | |
| HK40101911A (zh) | Shp2抑制剂的晶型 | |
| KR20210029694A (ko) | 2'-아미노-6-(2-아미노-6-메틸피리미딘-4-일)-3'-플루오로-[2,4'-바이피리딘]-5-올 2염산염 및 이를 포함하는 약제학적 조성물 | |
| TW202328152A (zh) | 氮雜內醯胺化合物之晶型 |